These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38655034)

  • 21. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
    Barkai LJ; Gonczi L; Balogh F; Angyal D; Farkas K; Farkas B; Molnar T; Szamosi T; Schafer E; Golovics PA; Juhasz M; Patai A; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Szekely H; Miheller P; Lakatos PL; Ilias A
    Sci Rep; 2024 Jun; 14(1):14909. PubMed ID: 38942890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
    Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN.
    Pujol-Muncunill G; Navas-López VM; Ledder O; Cohen S; Lekar M; Turner D; Kolho KL; Levine A; Croft NM; Bronsky J; Shouval DS; Assa A; Harris R; Kiparissi F; Aloi M; Afzal NA; Tzivinikos C; Barrio J; Norden C; Vega MJB; Buderus S; de Valderrama AF; de Ridder L; García-Romero R; Medina E; Sánchez C; Velasco M; Vicente S; Wilson DC; Naik S; Hradsky O; Cococcioni L; Martin-de-Carpi J
    Eur J Pediatr; 2024 Aug; 183(8):3253-3262. PubMed ID: 38700692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
    Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.
    Inniss S; Fragkos KC; Whitley L; Wimpory R; Rebello E; Lisboa A; Khetan T; Hassan J; Simpson K; Bhagwanani A; Vega R; Parisi I; Harrow P; Seward E; McCartney S; Bloom S; Smith AM; Plumb A; Rahman FZ
    Ther Adv Chronic Dis; 2023; 14():20406223231189072. PubMed ID: 37601038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
    Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study.
    Jeffrey AW; Picardo S; Menon S; So K; Venugopal K
    Ann Gastroenterol; 2023; 36(4):430-436. PubMed ID: 37396006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
    Casas-Deza D; Lamuela-Calvo LJ; Gomollón F; Arbonés-Mainar JM; Caballol B; Gisbert JP; Rivero M; Sánchez-Rodríguez E; Arias García L; Gutiérrez Casbas A; Merino O; Márquez L; Laredo V; Martín-Arranz MD; López Serrano P; Riestra Menéndez S; González-Muñoza C; de Castro Parga L; Calvo Moya M; Fuentes-Valenzuela E; Esteve M; Iborra M; Dura Gil M; Barreiro-De Acosta M; Lorente-Poyatos RH; Manceñido N; Calafat M; Rodríguez-Lago I; Guardiola Capo J; Payeras MA; Morales Alvarado VJ; Tardillo C; Bujanda L; Muñoz-Nuñez JF; Ber Nieto Y; Bermejo F; Almela P; Navarro-Llavat M; Martínez Montiel P; Rodríguez Gutiérrez C; Van Domselaar M; Sesé E; Martínez Pérez T; Ricart E; Chaparro M; García MJ; López-Sanromán A; Sicilia B; Orts B; López-García A; Martín-Arranz E; Pérez-Calle JL; de Francisco R; García-Planella E; Domènech E; García-López YS
    J Crohns Colitis; 2023 Jan; 17(1):83-91. PubMed ID: 35913456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
    Zhdanava M; Ding Z; Manceur AM; Zhao R; Holiday C; Kachroo S; Izanec J; Pilon D
    Curr Med Res Opin; 2023 Sep; 39(9):1215-1225. PubMed ID: 37563994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London.
    Kamperidis N; Shah M; Young S; Galimov E; Sweeney S; Arebi N
    Expert Opin Biol Ther; 2023; 23(12):1317-1329. PubMed ID: 38009339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
    Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
    J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.